WO2011050222A3 - Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv - Google Patents

Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv Download PDF

Info

Publication number
WO2011050222A3
WO2011050222A3 PCT/US2010/053637 US2010053637W WO2011050222A3 WO 2011050222 A3 WO2011050222 A3 WO 2011050222A3 US 2010053637 W US2010053637 W US 2010053637W WO 2011050222 A3 WO2011050222 A3 WO 2011050222A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disrupt
therapeutic compositions
ring structure
treating hiv
Prior art date
Application number
PCT/US2010/053637
Other languages
French (fr)
Other versions
WO2011050222A2 (en
Inventor
Philip Berman
Sara O'rourke
William Scott
Original Assignee
The Regents Of The University Of California Office Of Technology Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California Office Of Technology Transfer filed Critical The Regents Of The University Of California Office Of Technology Transfer
Priority to US13/079,472 priority Critical patent/US9782472B2/en
Publication of WO2011050222A2 publication Critical patent/WO2011050222A2/en
Publication of WO2011050222A3 publication Critical patent/WO2011050222A3/en
Priority to US15/694,388 priority patent/US10201603B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The Invention relates to therapeutic compositions and methods for treating HIV and other viral diseases and to vaccines for preventing HIV and other viral diseases.
PCT/US2010/053637 2008-10-04 2010-10-22 Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv WO2011050222A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/079,472 US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
US15/694,388 US10201603B2 (en) 2008-10-04 2017-09-01 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25385809P 2009-10-22 2009-10-22
US61/253,858 2009-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/055747 Continuation-In-Part WO2011057160A2 (en) 2008-10-04 2010-11-05 Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/059583 Continuation-In-Part WO2010040136A2 (en) 2008-10-04 2009-10-05 Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies
US13/079,472 Continuation-In-Part US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Publications (2)

Publication Number Publication Date
WO2011050222A2 WO2011050222A2 (en) 2011-04-28
WO2011050222A3 true WO2011050222A3 (en) 2011-09-09

Family

ID=43900971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/053637 WO2011050222A2 (en) 2008-10-04 2010-10-22 Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv

Country Status (1)

Country Link
WO (1) WO2011050222A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191481A1 (en) * 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220536A1 (en) * 2004-05-14 2009-09-03 Gilad Ofek HIV vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-HIV-1 antibodies against the membrane proximal domain of HIV GP41

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220536A1 (en) * 2004-05-14 2009-09-03 Gilad Ofek HIV vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-HIV-1 antibodies against the membrane proximal domain of HIV GP41

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEWLEY, C. A. ET AL.: "Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.", J. BIOL. CHEM., vol. 277, no. 16, 2002, pages 14238 - 14245, XP002392757, DOI: doi:10.1074/jbc.M201453200 *
HE, Y. ET AL.: "Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.", J. VIROL., vol. 82, no. 22, 2008, pages 11129 - 11139 *
HE, Y. ET AL.: "Identification of a critical motif for the human immunodeficiency virus type 1(HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors.", J. VIROL., vol. 82, no. 13, 2008, pages 6349 - 6358, XP002548682, DOI: doi:10.1128/JVI.00319-08 *

Also Published As

Publication number Publication date
WO2011050222A2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2013085550A3 (en) V1v2 immunogens
MX2013012053A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
MD20140035A2 (en) Method for treating hepatitis C virus
WO2012047856A3 (en) Novel inhibitors of secretion of hepatitis b virus antigens
ZA201108330B (en) Anti cxcr4 antibodies for the treatment of hiv
WO2012106356A3 (en) Virus-like particles and methods of use
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
IN2015DN02826A (en)
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011133729A3 (en) Anti-viral compounds
EP2841107A4 (en) Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
ZA201105343B (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2012047267A3 (en) Polyvalent immunogen
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
IN2014KN02740A (en)
WO2011098778A3 (en) Peptides for vaccines against birch allergy
MX2013003245A (en) Bvdv vaccine.
WO2011133707A3 (en) Anti-viral compounds
MX344189B (en) Formulations of mazindol.
WO2012031237A8 (en) Fused tricyclic ether carbamates and their use
EP2635300A4 (en) Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
WO2014022475A3 (en) Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
WO2012139097A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
MX350718B (en) Equine rhinitis vaccine.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10825713

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10825713

Country of ref document: EP

Kind code of ref document: A2